Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00330369 · ClinicalTrials.gov registry record · Phase 3
DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 352
- Enrollment target
NCT00330369: Completed Phase 3 study, sponsored by Gilead Sciences.
NCT00330369 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 352 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00330369, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 352 participants
- Enrollment target
Study Summary
This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the U.S. Food and Drug Administration (FDA) for use in the United States, which means that a doctor cannot prescribe this drug. The purpose of this study is to determine if darusentan is effective in reducing systolic blood pressure in subjects with resistant systolic hypertension, despite treatment with full doses of three or more antihypertensive drugs, including a diuretic.
Interventions
- DRUG Darusentan
- DRUG Darusentan Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 352 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-01 |
| Phase | Phase 3 |
What the finished NCT00330369 record still lists
NCT00330369 is an interventional study that assigns participants to a tested intervention. The registered 352 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% lower).
The record links to 0 conditions, and to 2 interventions - of which Darusentan is the first listed.
NCT00330369 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00330369 about?
NCT00330369 is a clinical study titled "DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension". This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the U.S. Food and Drug Administration (FDA) for use in the United States, which means that a doctor cannot prescribe this drug. The purpose of this study is to determine if darusentan is ef...
What is the current status of trial NCT00330369?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 352 participants. The study started on 2006-06. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00330369?
The interventions under investigation include: Darusentan (DRUG), Darusentan Placebo (DRUG).
Who is sponsoring clinical trial NCT00330369?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00330369's enrollment target sits among peer trials
352 1030th of 2000 higher than 968 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05811936 · 352 participants · NA
The SNAP Tool for Head and Neck Cancer Survivor-Caregiver Dyads
- NCT06258941 · 352 participants · Phase 1
Classroom Break, Cognition, and Fitness in Elementary School Children
- NCT06269081 · 352 participants · NA
Testing Two Interventions to Improve Health Outcomes and Quality of Life Among Rural Older Adults Living With HIV
- NCT06337292 · 352 participants · Phase 3
Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk Fractures
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia